Merck's Keytruda and Lynparza combination failed to extend survival in metastatic nonsquamous non-small cell lung cancer patients.

Merck's combination of Keytruda and Lynparza failed to meet main goals in a late-stage study evaluating it as an initial treatment for a type of lung cancer. The treatment did not extend survival in patients or improve survival without disease worsening in certain patients with metastatic nonsquamous non-small cell lung cancer. Merck stated a full evaluation of the studies is underway.